Income Statement
IRONWOOD PHARMACEUTICALS INC
IRWD
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Dec 31, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
296.15 | 351.41 | 442.74 | 410.60 | 413.75 | 389.52 | 428.41 | 346.64 | 298.28 | 273.96 | 149.56 | 76.44 | 22.88 | 150.25 | 65.87 |
|
Cost of Revenue
|
- | - | - | - | - | 3.14 | 23.88 | 32.75 | 19.10 | 1.87 | 0.01 | 25.58 | 7.20 | 0.97 | - |
|
Gross Profit
|
296.15 | 351.41 | 442.74 | 410.60 | 413.75 | 386.39 | 404.54 | 313.89 | 279.18 | 272.09 | 149.54 | 50.85 | 15.68 | 149.28 | 65.87 |
|
Operating Expenses
|
177.39 | 255.69 | 274.40 | 160.26 | 181.54 | 228.07 | 287.49 | 407.79 | 381.35 | 312.77 | 233.99 | 220.22 | 225.61 | 206.01 | 132.01 |
|
Research & Development
|
95.14 | 111.42 | 116.09 | 44.27 | 70.41 | 88.06 | 115.04 | 166.50 | 148.23 | 139.49 | 108.75 | 101.89 | 102.38 | 113.47 | 86.09 |
|
Selling, General & Administrative
|
82.26 | 144.27 | 158.31 | 115.99 | 111.13 | 140.00 | 172.45 | 241.29 | 233.12 | 173.28 | 125.25 | 118.33 | 123.23 | 92.54 | 45.92 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
118.76 | 95.72 | 168.34 | 250.34 | 232.22 | 158.32 | 117.04 | -93.91 | -102.17 | -40.68 | -84.45 | -169.37 | -209.93 | -56.73 | -66.14 |
|
Non-Operating Income
|
-28.48 | -27.93 | -2.64 | 2.09 | -31.60 | -34.08 | -61.18 | -43.48 | -39.55 | -29.84 | -40.58 | -20.25 | -20.81 | 0.14 | 1.29 |
|
Interest Income
|
- | - | - | - | 0.60 | - | - | - | - | - | - | - | - | 0.20 | 0.46 |
|
Interest Expense
|
29.05 | 28.48 | 21.63 | 7.60 | 31.15 | 29.48 | 36.60 | 37.72 | 36.37 | 39.15 | 31.10 | 21.17 | 21.00 | 0.06 | 0.06 |
|
Other Non-Op Income / Expense
|
0.19 | 0.64 | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Income Before Tax
|
70.03 | 65.20 | -948.07 | 252.42 | 200.66 | 108.86 | - | - | - | - | - | - | -272.81 | -72.62 | -64.85 |
|
Income Tax Expense
|
46.01 | 64.32 | 54.17 | 77.36 | -327.79 | 2.69 | - | - | - | - | - | - | - | - | 0.00 |
|
Non-Controlling Interest
|
- | - | -29.32 | - | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
24.02 | 0.88 | -1,002.24 | 175.07 | 528.45 | 106.18 | 21.51 | -282.37 | -116.94 | - | - | - | - | -72.62 | -64.85 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Dec 31, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
118.76 | 95.72 | 168.34 | 250.34 | 232.22 | 158.32 | 117.04 | -87.79 | -93.77 | -30.41 | -72.82 | -157.04 | -198.20 | -45.41 | -56.14 |
|
Earnings Per Share (Basic)
|
0.15 | 0.01 | -6.45 | 1.13 | 3.26 | 0.67 | 0.14 | - | - | - | - | - | -2.35 | -0.68 | - |
|
Diluted EPS
|
0.15 | 0.01 | -6.45 | 0.96 | 3.21 | 0.66 | 0.14 | - | - | - | - | - | -2.35 | -0.68 | - |
|
Weighted Average Shares
|
161.84 | 159.08 | 155.44 | 154.37 | 162.25 | 159.43 | - | - | - | - | - | - | - | - | 99.87 |
|
Diluted Weighted Avg Shares
|
162.98 | 160.08 | 155.44 | 186.31 | 164.42 | 160.66 | - | - | - | - | - | - | - | - | 99.87 |
|
Comprehensive Income
|
22.03 | 4.83 | -1,005.21 | 175.07 | 528.45 | 106.18 | 21.51 | -282.29 | -117.01 | -81.63 | -142.74 | -189.64 | -272.82 | -72.63 | - |